Desk›Healthcare› Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd
BSE 544319 · NSE SENORES · ISIN INE0RB801010 · Group A · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹1,482.35
+0.67%
BSE close, 28 August 2026
₹6,826.75 cr
4.6 cr shares · Small cap
₹3,666.25 cr
as published
366.9× · —
EPS ₹4.04 · BV —
106.09 / 20.25
₹ cr, as filed
38
8 selected · 21%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -7.3% |
|---|---|
| Against 52-week low | +124.0% |
| Day change | +0.67% |
| Size band | Small cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹4.04 |
|---|---|
| Price / earnings | 366.92× |
| Price / book | — |
| Book value — derived, price ÷ P/B | — |
| Return on equity | — |
| Operating margin | 26.75% |
| Net margin | 3.82% |
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 26.99 | 1.03 | 0.22 | 26.75% | 3.82% |
| Mar-26 · Q | 36.81 | 8.48 | 1.84 | 50.83% | 23.04% |
| FY25-26 | 106.09 | 20.25 | 4.40 | 44.93% | 19.09% |
Quarter on quarter
- Revenue, quarter on quarter
- -26.7%
- Net profit, quarter on quarter
- -87.9%
- Operating margin, quarter on quarter
- -2,408 bps
Disclosure profile 38 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Change in Management | 2 |
| Board Outcome | 1 |
| Concall Transcript | 1 |
| Investor Presentation | 1 |
| KMP | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 8 |
| Procedural | |
| Analyst / Investor Meet | 4 |
| AGM / EGM | 3 |
| General | 3 |
| Newspaper Publication | 3 |
| Annual Report | 2 |
| Other Update | 2 |
| Postal Ballot | 2 |
| SAST | 2 |
| Subsidiary Incorporation | 2 |
| BRSR | 1 |
| Board Meeting | 1 |
| Clarification | 1 |
| Compliance Certificate | 1 |
| Monitoring Agency | 1 |
| Outcome | 1 |
| Trading Window | 1 |
| Procedural sub-total | 30 |
| Total | 38 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
38 filings · 8 selected · busiest 2026-07-27
Filing rhythm · the twelve most recent
2026-09-032026-10-08
SelectedProcedural
Filings
38 in the window · 11 earlier on record
-
8 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Senores Pharmaceuticals Limited has informed the Exchange about the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended September 30, 2026
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
28 September 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer's Report
Senores Pharmaceuticals Limited has informed the Exchange regarding Scrutinizer Report and Voting results of 09th Annual General Meeting
AGM/EGM / AGM View filing →
-
25 September 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of the 9th Annual General Meeting of the Company held on September 25, 2026
AGM/EGM / AGM View filing →
-
24 September 2026 ·
Closure of Trading Window
Intimation pertaining to closure of trading window
Insider Trading / SAST / Closure of Trading Window View filing →
-
21 September 2026 ·
Clarification On Movement In Volume
Clarification Letter on volume movement in the scrip of the Company
Company Update / General View filing →
-
21 September 2026 ·
Clarification sought from Senores Pharmaceuticals Ltd
The Exchange has sought clarification from Senores Pharmaceuticals Ltd on September 21, 2026, with reference to Movement in Volume. The reply is awaited.
Company Update / Clarification
-
11 September 2026 ·
Successful Completion Of USFDA Inspection
We are pleased to announce that the USFDA has successfully completed its inspection at the manufacturing facility of Apnar Pharma Private Limited
Company Update / General View filing →
-
9 September 2026 ·
Reg. 34 (1) Annual Report.
We are submitting herewith the Corrigendum to the Annual Report of the Company for the financial year 2025-26.
Others / Reg. 34 (1) Annual Report View filing →
-
4 September 2026 ·
Newspaper Publication
We are enclosing herewith the Newspaper Publication for the 9th Annual General Meeting of the Company.
Company Update / Newspaper Publication View filing →
-
3 September 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
We are submitting herewith the copy of Business Responsibility and Sustainability Report of the Company for the financial year 2025-26.
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
3 September 2026 ·
Reg. 34 (1) Annual Report.
We are submitting herewith the Annual Report of the Company for the financial year 2025-26.
Others / Reg. 34 (1) Annual Report View filing →
-
3 September 2026 ·
Shareholder Meeting To Be Held On September 25, 2026 At 11:30 Am (IST)
We are submitting herewith the notice convening the 9th Annual general Meeting of the Company and Annual Report for the financial year 2025-26
AGM/EGM / AGM View filing →
-
27 August 2026 ·
Analyst / Investor Meet - Intimation
Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on September 02, 2026
Company Update / Analyst / Investor Meet View filing →
-
27 August 2026 ·
Newspaper Publication
Senores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcoming Annual General Meeting of the Company
Company Update / Newspaper Publication View filing →
-
26 August 2026 ·
Change in Management
Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Independent Director
Company Update / Change in Management View filing →
-
26 August 2026 ·
Appointment of Company Secretary and Compliance Officer
Senores Pharmaceuticals Limited has informed the Exchange regarding appointment of Company Secretary and Compliance Officer of the Company
Company Update / Appointment of Company Secretary / Compliance Officer View filing →
-
26 August 2026 ·
Acquisition
Senores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Subsidiary Company in Canada
Company Update / Acquisition View filing →
-
26 August 2026 ·
Acquisition
Senores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Wholly owned subsidiary in Mexico
Company Update / Acquisition View filing →
-
26 August 2026 ·
Board Meeting Outcome for Senores Pharmaceuticals Limited Has Informed The Exchange Regarding Outcome Of Board Meeting
Senores Pharmaceuticals Limited has informed the Exchange about Outcome of Board Meeting held on August 26, 2026
Others / Outcome without intimation View filing →
-
24 August 2026 ·
Intimation For Giving Corporate Guarantee For Credit Facilities Availed By Apnar Pharma Private Limited, Subsidiary Of The Company From ICICI Bank Limited
Senores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private Limited, Subsidiary of the Company from ....
Company Update / General View filing →
-
20 August 2026 ·
Analyst / Investor Meet - Intimation
Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on August 25, 2026
Company Update / Analyst / Investor Meet View filing →
-
12 August 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhananjay Barot
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
12 August 2026 ·
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashokkumar Vijaysinh Barot
Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 View filing →
-
4 August 2026 ·
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Senores Pharmaceuticals Limited has informed the Exchange regarding the Scrutinzer Report dated August 04, 2026
AGM/EGM / Postal Ballot View filing →
-
4 August 2026 ·
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Postal Ballot
AGM/EGM / Postal Ballot View filing →
-
3 August 2026 ·
Earnings Call Transcript
Senores Pharmaceuticals Limited has informed the Exchange regarding Transcript of Earnings Conference Call held on Monday, July 27, 2026 for Q1FY27.
Company Update / Earnings Call Transcript View filing →
-
28 July 2026 ·
Newspaper Publication
Senores Pharmaceuticals Limited has informed the Exchange regarding Newspaper Publication Extracts of Unaudited Financial Results of the Company for quarter ended June 30, 2026
Company Update / Newspaper Publication View filing →
-
27 July 2026 ·
Analyst / Investor Meet - Outcome
Senores Pharmaceuticals Limited has informed the Exchange regarding Audio recording of Earnings Conference Call for the quarter ended June 30, 2026
Company Update / Analyst / Investor Meet View filing →
-
27 July 2026 ·
Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue Of Convertible Equity Warrants, For The Quarter Ended On June 30, 2026
Senores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible ....
Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation View filing →
-
27 July 2026 ·
Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On June 30, 2026
Senores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended June 30, 2026
Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation View filing →
-
27 July 2026 ·
Monitoring Agency Report
Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for quarter ended June 30, 2026
Company Update / Monitoring Agency Report View filing →
-
27 July 2026 ·
Investor Presentation
Senores Pharmaceuticals Limited has informed the exchange regarding Investor Presentation for Q1FY27
Company Update / Investor Presentation View filing →
-
27 July 2026 ·
Press Release / Media Release
Senores Pharmaceuticals Limited has informed the exchange regarding Media Release dated July 27, 2026
Company Update / Press Release / Media Release View filing →
-
27 July 2026 ·
Change in Management
Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of Ms Anjali Shah as Assistant Vice President - Finance categorized as SMP of the Company w.e.f July 27, 2026
Company Update / Change in Management View filing →
-
27 July 2026 ·
Financial Results For Quarter Ended June 30, 2026
Senores Pharmaceuticals Limited has informed the exchange regarding Financial Results for quarter ended June 30, 2026
Result / Financial Results View filing →
-
27 July 2026 ·
Board Meeting Outcome for Outcome Of Board Meeting
Senores Pharmaceuticals Limited has informed exchange regarding Outcome of Board Meeting held on July 27, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
21 July 2026 ·
Analyst / Investor Meet - Intimation
Senores Pharmaceuticals Limited has informed the Exchange regarding Earnings Conference Call for Q1FY27 scheduled to be held on July 27, 2026 at 05:15 P.M. (IST)
Company Update / Analyst / Investor Meet View filing →
-
21 July 2026 ·
Board Meeting Intimation for Considering And Approving The Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter Ended June 30, 2026 And To Transact Other Business Matters
Senores Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2026 ,inter alia, to consider and approve to consider and approve ....
Board Meeting / Board Meeting View filing →
RSS feed for Senores Pharmaceuticals Ltd · the 50 most recent filings